

## Targeted Genes and Methodology Details for Bleeding Disorders, Focused Gene Panel

The following applies to GNBLF / Bleeding Disorders, Focused Gene Panel, Next-Generation Sequencing. Testing is performed to evaluate for the presence of variants in coding regions and extending to +/- 10 base pairs of adjacent intronic sequence on either side of the coding exons of the genes analyzed. In addition, the analysis will cover select non-coding variants. Next-generation sequencing and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of copy number variants in the genes analyzed. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

This list is current from June 2023 to the present. This document is intended to highlight additional evaluations for variants of high clinical interest as well as technical limitations. However, this document does not comprehensively reflect all genomic regions covered by this test. For questions regarding transcripts, genes, or regions covered, contact the laboratory at 800-533-1710.

Genomic Build: GRCh37 (hg19) unless otherwise specified

Gene	Reference Transcript	Additional Evaluations	Technical Limitations
F7	NM_000131.4	c130 to c1, c.681+132G>T	-
F8	NM_000132.3	+/- 30 bp, c270 to c1, c.5587-93C>T, c.5998+182A>G, c.5999-277G>A, c.*1 to c.*70	-
F9	NM_000133.4	+/- 30 bp, c70 to c1, c.*980 to c.*1370	-
F11	NM_000128.4	c.485+122T>A	-
GP1BA	NM_000173.7	-	Sequence variants in exon 2 may not be detected or reported
VWF	NM_000552.4	-	Sequence variants and CNV in exons 23–34 may not be detected or reported  Duplication analysis for CNV in exon 26 will not be performed